| Name | Title | Contact Details |
|---|
RegenScientific, a wholly-owned business unit of Cytophil, Inc., an ISO 13485 certified company, is dedicated to providing physicians and patients with high-quality, safe, efficacious, and cost-effective soft tissue augmentation implants. The company has CE-Mark for its Renú® Soft Tissue (Volumizing) Implant for lipoatrophy, vocal fold insufficiency, and soft tissue augmentation in Europe. The Company has FDA 510k clearances for its Renú® Gel and Renú® Voice otolaryngology products indicated for vocal fold injection augmentation. Renú® is a registered trademark of Cytophil, Inc. REGENSCIENTIFIC™ and the REGENSCIENTIFIC logo are trademarks of Cytophil, Inc.
Fruit Street delivers the CDC`s Diabetes Prevention Program using telehealth, wearable devices, and mobile applications. The diabetes prevention program is a 1-year long diet and lifestyle intervention designed to help pre-diabetic patients lose 5-7% of their weight through diet and lifestyle changes. The program is based on clinical research that was published in the New England Journal of Medicine in 2002 which showed that patients who complete the program have a 58% risk reduction for developing diabetes.
NES Healthcare Group is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. NES Healthcare Group is based in Tiburon, CA. You can find more information on NES Healthcare Group at www.neshold.com
Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare diseases. Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders, reaching a total of over 20 therapies in various stages of development. The Company`s programs span across several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is poised to be the most meaningful precision genetic medicine company in the world and make a profound difference in the lives of patients suffering from rare neuromuscular diseases and other rare diseases.
Xagenic is a molecular diagnostics company developing a true point- of-care platform. Our aim is to enable on-demand, near patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of first consultation. This will dramatically improve patient care and reduce health care costs.